Studies of SARS virus vaccines
- PMID: 18708674
Studies of SARS virus vaccines
Abstract
1. Intranasal vaccination using inactivated SARS coronavirus (SARS-CoV) vaccine with adjuvant can induce strong systemic (serum immunoglobulin [Ig] G) and respiratory tract local (tracheal-lung wash fluid IgA) antibody responses with neutralising activity. 2. RBD-Fc (protein-based vaccine) is able to induce effective neutralising antibodies able to provide protection from SARS-CoV infection in animal models. 3. A single dose of RBD-rAAV vaccination can induce adequate neutralising antibody against SARS-CoV infection. 4. Additional doses of vaccine increased the production of neutralising antibody 5-fold compared with a single dose. 5. RBD-rAAV vaccination provoked a prolonged antibody response with continually increasing levels of neutralising activity. 6. Intranasal vaccination with RBD-rAAV induced local IgA and systemic IgG neutralising antibodies and specific T-cell responses, able to protect against SARS-CoV infection in animal models. 7. When compared with the RBD-rAAV prime/boost vaccination, RBD-rAAV prime/RBD-peptide boost induced similar levels of Th1 and neutralising antibody responses that protected vaccinated mice from subsequent SARS-CoV challenges,but stronger Th2 and CTL responses. 8. Overall, our findings suggest that the inactivated vaccine, RBD-Fc and RBD-rAAV, can be further developed into effective and safe vaccines against SARS and that intranasal vaccination may be the preferred route of administration.
Similar articles
-
Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection.Vaccine. 2008 Mar 20;26(13):1644-51. doi: 10.1016/j.vaccine.2008.01.025. Epub 2008 Feb 4. Vaccine. 2008. PMID: 18289745 Free PMC article.
-
Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.J Immunol. 2008 Jan 15;180(2):948-56. doi: 10.4049/jimmunol.180.2.948. J Immunol. 2008. PMID: 18178835 Free PMC article.
-
Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model.Vaccine. 2007 Apr 12;25(15):2832-8. doi: 10.1016/j.vaccine.2006.10.031. Epub 2006 Oct 30. Vaccine. 2007. PMID: 17092615 Free PMC article.
-
Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus.Avian Pathol. 2003 Dec;32(6):567-82. doi: 10.1080/03079450310001621198. Avian Pathol. 2003. PMID: 14676007 Free PMC article. Review.
-
Vaccine design for severe acute respiratory syndrome coronavirus.Viral Immunol. 2005;18(2):327-32. doi: 10.1089/vim.2005.18.327. Viral Immunol. 2005. PMID: 16035944 Review.
Cited by
-
Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.Allergy. 2020 Jul;75(7):1564-1581. doi: 10.1111/all.14364. Allergy. 2020. PMID: 32396996 Free PMC article. Review.
-
A phase trial of the oral Lactobacillus casei vaccine polarizes Th2 cell immunity against transmissible gastroenteritis coronavirus infection.Appl Microbiol Biotechnol. 2016 Sep;100(17):7457-69. doi: 10.1007/s00253-016-7424-9. Epub 2016 Mar 28. Appl Microbiol Biotechnol. 2016. PMID: 27020282 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
